Published on BostInno / November 2, 2016

Dylan Martin

Nineteen of Boston’s most promising early-stage startups just got a nice cash infusion of $1.5 million. That’s the total amount of money the MassChallenge Boston finalists were awarded at the startup accelerator’s awards ceremony Wednesday night.

The accelerator’s top three winners — Adhesys Medical, EYL and TellusLabs — each walked away with $100,000 while two other startups each won $75,000, with another 11 each receiving $50,000 each — all from MassChallenge. An additional three startups — Angiex, Dover Lifesciences and LambdaVision — won a share of $500,000 from CASIS and Boeing.

The nineteen were chosen out of MassChallenge’s top 26 startups from this year’s program, which had a total of 128 startups participating, and they represented a wide variety of categories from advanced surgical glue and Internet of Things security software to gadgets that inspire young girls to get into STEM. The program, which ran from May to October, received over 1,700 applications, making this year’s cohort the program’s most competitive group yet.

“I’m so proud to announce this year’s winning startups, which have leveraged our global network of resources, mentors, partners, and more to truly change the world,” Scott Bailey, managing director of MassChallenge Boston, said. “Tonight is not only a celebration of them, but of all of our startups and key players across the ecosystem who have made a commitment to work together in order to create enormous impact.”

CASIS-Boeing Prize for Technology in Space – $500,000

Angiex, Inc. — USA – Massachusetts | Healthcare/Life Sciences  — Pioneering a vascular therapy for solid tumors. In preclinical studies, an Angiex antibody-drug conjugate regressed solid tumors.

Dover Lifesciences — USA – Massachusetts | Healthcare/Life Sciences — Creating new drugs to treat metabolic and cardiovascular diseases by mimicking favorable genotypes/phenotypes in nature.

LambdaVision, Inc. — USA – Connecticut | Healthcare/Life Sciences  — Developing a protein-based retinal implant to restore vision to the millions blinded by retinal degenerative diseases.